Obesity, obesity-related metabolic conditions, and risk of thyroid cancer in women: results from a prospective cohort study (Sister Study).
Diabetes
Epidemiology
Obesity
Obesity associated diseases
Risk factors
Thyroid cancer
Journal
Lancet regional health. Americas
ISSN: 2667-193X
Titre abrégé: Lancet Reg Health Am
Pays: England
ID NLM: 9918232503006676
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
20
02
2023
revised:
02
06
2023
accepted:
02
06
2023
medline:
22
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
Thyroid cancer incidence has increased worldwide. Obesity trends may play a role, but the underlying biological pathways are not well-characterized. Therefore, we examined associations of excess adiposity and obesity-related metabolic conditions with thyroid cancer incidence. From the Sister Study, a cohort of sisters of women with breast cancer, we included 47,739 women who were cancer-free at baseline (2003-2009). Height, weight, waist and hip circumference, and blood pressure were measured at baseline and medical history was self-reported. Cox proportional hazards regression models were adjusted for age (time scale), race/ethnicity, smoking, baseline history of benign thyroid disease, and frequency of routine healthcare visits. During follow-up (median = 12.5; max = 15.9 years), 259 women reported incident thyroid cancer. Body mass index (BMI) (hazard ratio [HR] In this cohort of sisters of women diagnosed with breast cancer, excess adiposity and several obesity-related metabolic conditions were associated with thyroid cancer incidence. These findings provide insights into potential biological mechanisms linking obesity and thyroid cancer. This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute and National Institute of Environmental Health Sciences (Z01-ES044005).
Sections du résumé
Background
UNASSIGNED
Thyroid cancer incidence has increased worldwide. Obesity trends may play a role, but the underlying biological pathways are not well-characterized. Therefore, we examined associations of excess adiposity and obesity-related metabolic conditions with thyroid cancer incidence.
Methods
UNASSIGNED
From the Sister Study, a cohort of sisters of women with breast cancer, we included 47,739 women who were cancer-free at baseline (2003-2009). Height, weight, waist and hip circumference, and blood pressure were measured at baseline and medical history was self-reported. Cox proportional hazards regression models were adjusted for age (time scale), race/ethnicity, smoking, baseline history of benign thyroid disease, and frequency of routine healthcare visits.
Findings
UNASSIGNED
During follow-up (median = 12.5; max = 15.9 years), 259 women reported incident thyroid cancer. Body mass index (BMI) (hazard ratio [HR]
Interpretation
UNASSIGNED
In this cohort of sisters of women diagnosed with breast cancer, excess adiposity and several obesity-related metabolic conditions were associated with thyroid cancer incidence. These findings provide insights into potential biological mechanisms linking obesity and thyroid cancer.
Funding
UNASSIGNED
This research was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute and National Institute of Environmental Health Sciences (Z01-ES044005).
Identifiants
pubmed: 37346380
doi: 10.1016/j.lana.2023.100537
pii: S2667-193X(23)00111-4
pmc: PMC10279535
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100537Déclaration de conflit d'intérêts
All authors declare no conflict of interest.
Références
Cancer. 2017 Feb 1;123(3):372-381
pubmed: 27741354
J Natl Cancer Inst. 2014 Jun;106(6):dju097
pubmed: 24824312
Cancer Causes Control. 2011 May;22(5):743-51
pubmed: 21380729
Nat Rev Cancer. 2004 Aug;4(8):579-91
pubmed: 15286738
Thyroid. 2010 Nov;20(11):1285-93
pubmed: 20932181
Arch Intern Med. 2008 Mar 24;168(6):587-92
pubmed: 18362250
Lancet Diabetes Endocrinol. 2021 Feb;9(2):57-59
pubmed: 33347808
Endocr Relat Cancer. 2020 Apr;27(4):245-259
pubmed: 32045361
Curr Opin Obstet Gynecol. 2017 Dec;29(6):390-396
pubmed: 28901968
Cancer Prev Res (Phila). 2014 Apr;7(4):418-25
pubmed: 24449056
Thyroid. 2019 Mar;29(3):349-358
pubmed: 30648486
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Ann Oncol. 2021 Mar;32(3):351-359
pubmed: 33516778
Thyroid. 2020 Oct;30(10):1496-1504
pubmed: 32524894
Thyroid. 2022 Mar;32(3):306-314
pubmed: 34915752
Int J Cancer. 2015 Mar 1;136(5):1218-27
pubmed: 25041790
Endocr Pract. 2015 Jun;21(6):686-96
pubmed: 26135963
J Natl Cancer Inst. 2020 Aug 1;112(8):810-817
pubmed: 31638139
Eur Thyroid J. 2012 Oct;1(3):159-67
pubmed: 24783015
Environ Health Perspect. 2017 Dec 20;125(12):127003
pubmed: 29373861
Thyroid. 2016 Feb;26(2):306-18
pubmed: 26756356
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
JAMA Oncol. 2019 Jan 1;5(1):106-107
pubmed: 30489606
PLoS One. 2022 Jul 28;17(7):e0271038
pubmed: 35901016
Am J Epidemiol. 2010 Jan 15;171(2):242-52
pubmed: 19951937
Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):358-363
pubmed: 32740043
Lancet Diabetes Endocrinol. 2021 Apr;9(4):225-234
pubmed: 33662333
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
PLoS One. 2012;7(7):e39504
pubmed: 22815707
Thyroid. 2018 Jul;28(7):864-870
pubmed: 29808777